"Lopinavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A.
| Descriptor ID |
D061466
|
| MeSH Number(s) |
D03.383.742.698.553
|
| Concept/Terms |
Lopinavir- Lopinavir
- N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
|
Below are MeSH descriptors whose meaning is more general than "Lopinavir".
Below are MeSH descriptors whose meaning is more specific than "Lopinavir".
This graph shows the total number of publications written about "Lopinavir" by people in this website by year, and whether "Lopinavir" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 5 | 5 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 3 | 3 |
| 2007 | 1 | 6 | 7 |
| 2008 | 0 | 9 | 9 |
| 2009 | 0 | 8 | 8 |
| 2010 | 0 | 8 | 8 |
| 2011 | 5 | 6 | 11 |
| 2012 | 4 | 4 | 8 |
| 2013 | 3 | 3 | 6 |
| 2014 | 5 | 5 | 10 |
| 2015 | 7 | 3 | 10 |
| 2016 | 2 | 2 | 4 |
| 2017 | 2 | 3 | 5 |
| 2018 | 4 | 3 | 7 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 5 | 6 |
| 2021 | 3 | 7 | 10 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 2 | 4 |
Below are the most recent publications written about "Lopinavir" by people in Profiles.
-
Effects of Combination of Ethanol With Ritonavir, Lopinavir or Darunavir on Expression and Localization of the ER-Associated Set Protein and Infection of HIV-1 Pseudovirus in Primary Human Cells. J Acquir Immune Defic Syndr. 2024 06 01; 96(2):e6-e10.
-
Systemic inflammation in pregnant women with HIV: relationship with HIV treatment regimen and preterm delivery. AIDS. 2024 07 01; 38(8):1111-1119.
-
Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial. Lancet HIV. 2024 02; 11(2):e86-e95.
-
Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age. Pediatr Infect Dis J. 2024 Apr 01; 43(4):355-360.
-
Modern antiretroviral regimens in pregnant women: virologic outcomes and durability. AIDS. 2024 01 01; 38(1):21-29.
-
Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial. J Acquir Immune Defic Syndr. 2023 04 15; 92(5):393-398.
-
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA. 2023 01 03; 329(1):39-51.
-
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clin Pharmacol Ther. 2023 03; 113(3):660-669.
-
Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. Pharmacotherapy. 2023 07; 43(7):638-649.
-
Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study. J Acquir Immune Defic Syndr. 2022 03 01; 89(3):324-331.